|
Clinical features
|
Total (n = 726)
|
UGT1A1*28
|
UGT1A1*6
|
|---|
|
*1/*1 (n = 579)
|
*28/− (n = 147)
|
P value
|
*1/*1 (n = 493)
|
*6/− (n = 233)
|
P value
|
|---|
|
Age, years
|
41 ± 14
|
41 ± 14
|
41 ± 15
|
0.816
|
41 ± 14
|
42 ± 14
|
0.799
|
|
Male sex, n (%)
|
400 (55.1)
|
317 (54.7)
|
83 (56.5)
|
0.709
|
280 (56.8)
|
120 (51.5)
|
0.181
|
|
Smoking, n (%)
|
171(23.6)
|
141 (24.4)
|
30 (20.4)
|
0.314
|
125 (25.4)
|
46 (19.7)
|
0.096
|
|
Drinking, n (%)
|
108 (14.9)
|
91 (15.7)
|
17 (11.6)
|
0.206
|
69 (14.0)
|
39 (16.7)
|
0.332
|
|
FAB classification, n (%)
|
|
M0
|
3 (0.4)
|
2 (0.3)
|
1 (0.7)
|
0.918
|
1 (0.2)
|
2 (0.9)
|
0.204
|
|
M1
|
38 (5.2)
|
10 (5.2)
|
11 (7.5)
| |
33 (6.7)
|
8 (3.4)
| |
|
M2
|
372 (51.2)
|
298 (51.5)
|
74 (50.3)
| |
258 (52.3)
|
114 (48.9)
| |
|
M4
|
149 (20.5)
|
118 (20.4)
|
28 (19.0)
| |
94 (19.1)
|
52 (23.3)
| |
|
M5
|
146 (20.1)
|
117 (20.2)
|
29 (19.7)
| |
97 (19.7)
|
49 (21.0)
| |
|
M6
|
17 (2.3)
|
13 (2.2)
|
4 (2.7)
| |
9 (1.8)
|
8 (3.4)
| |
|
M7
|
1 (0.1)
|
1 (0.2)
|
–
| |
1 (0.2)
|
–
| |
|
AML type, n (%)
|
|
De novo AML
|
692 (95.3)
|
551 (95.2)
|
141 (95.9)
|
0.699
|
469 (95.1)
|
223 (95.7)
|
0.732
|
|
Secondary AML
|
34 (4.7)
|
28 (4.8)
|
6 (4.1)
| |
24 (4.9)
|
10 (4.7)
| |
|
Parameters at diagnosis
|
|
WBC count, × 109/l
|
40.07 ± 62.15
|
39.54 ± 62.53
|
42.17 ± 60.80
|
0.650
|
40.70 ± 59.07
|
38.72 ± 68.37
|
0.691
|
|
RBC count, × 1012/l
|
2.33 ± 1.64
|
2.26 ± 0.77
|
2.60 ± 3.33
|
0.232
|
2.39 ± 1.93
|
2.21 ± 0.73
|
0.173
|
|
Hemoglobin, g/l
|
73.98 ± 21.68
|
73.64 ± 21.86
|
75.36 ± 20.99
|
0.395
|
74.61 ± 22.25
|
72.66 ± 20.44
|
0.261
|
|
Platelets count, × 109/l
|
55.41 ± 64.40
|
54.70 ± 60.73
|
58.22 ± 77.45
|
0.559
|
53.90 ± 61.17
|
58.62 ± 70.80
|
0.360
|
|
Neutrophil count, × 109/l
|
13.44 ± 33.00
|
13.51 ± 34.56
|
13.14 ± 26.04
|
0.905
|
13.98 ± 32.47
|
12.29 ± 34.23
|
0.525
|
|
LDH, U/l
|
564.6 ± 725.2
|
561.2 ± 771.9
|
578.2 ± 501.1
|
0.806
|
566.4 ± 758.5
|
560.9 ± 651.7
|
0.926
|
|
Bone marrow blasts, %
|
65.37 ± 20.88
|
64.94 ± 20.81
|
67.02 ± 21.12
|
0.291
|
65.98 ± 21.21
|
64.08 ± 20.15
|
0.267
|
|
Risk stratifications, n (%)
|
|
Low risk
|
152 (20.9)
|
115 (19.9)
|
37 (25.2)
|
0.553
|
98 (19.9)
|
54 (23.2)
|
0.142
|
|
Intermediate risk
|
330 (45.5)
|
267 (46.1)
|
63 (42.9)
| |
230 (46.7)
|
100 (42.9)
| |
|
High risk
|
140 (19.3)
|
114 (19.7)
|
26 (17.7)
| |
102 (20.7)
|
38 (16.3)
| |
|
Unknown
|
104 (14.3)
|
83(14.3)
|
21 (14.3)
| |
63 (12.8)
|
41 (17.6)
| |
|
HSCT, n (%)
|
124 (17.1)
|
94 (16.2)
|
30 (20.4)
|
0.230
|
89 (18.1)
|
35 (15.0)
|
0.311
|
- *28/− or *6/− represents mutant homozygous and heterozygous of corresponding loci on UGT1A1
- Risk stratification based on NCCN guidelines version 1.2015 acute myeloid leukemia
- FAB Classification French–Britain–American Classification, HSCT hematopoietic stem cell transplantation, LDH lactate dehydrogenase, RBC red blood cell, WBC white blood cell
- P value was based on χ2 test for categorical variables and student’s t test for continuous variables
